Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Posts 21 Percent Revenue Growth for Q1

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic Health reported after the close of the market Tuesday that its first-quarter revenues increased 21 percent year over year, with product sales climbing 23 percent.

The Redwood City, Calif.-based molecular diagnostics firm generated total revenues of $49.8 million for the three-month period ended March 31, compared to $41.2 million for the first quarter of 2010. Its product sales were $49.5 million versus $40.3 million. Genomic Health beat Wall Street estimates of $48.7 million for the quarter.

The company said that more than 16,230 Oncotype DX test results were delivered in the first quarter, up 22 percent from 13,310 test results delivered in the first quarter of 2010.

The firm's net loss for the quarter was $286,000, or $.01 per share, for the quarter compared to a net loss of $1.9 million, or $.07 per share, for Q1 2010. Analysts, on average, had expected a profit of $.02 per share.

Genomic Health spent $10.1 million on R&D during the quarter, up 29 percent from $7.8 million. Its SG&A spending increased 17 percent to $30.9 million from $26.3 million.

Genomic Health finished the quarter with $18.2 million in cash and cash equivalents and $45.4 million in short-term investments.

During a conference call following the release of the results, Genomic Health President and CEO Kim Popovits noted that the firm has invested a total of $2.8 million in two genomics startups over the last two quarters: Locus Development and Station X. Both are in stealth mode and the investments are in line with the company's move into next-gen sequencing for biomarker discovery.

The firm said that it expects to report total revenues of $200 million to $210 million for full-year 2011, and net income of $3 million to $5 million.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.